[B032] 药物临床结果基本信息的接口地址是什么？

[B032] 药物临床结果基本信息的接口为 GET https://connect.zhihuiya.com/synapse/ct-result/detail。

[B032] 药物临床结果基本信息可以返回哪些数据？

[B032] 药物临床结果基本信息：通过临床结果ID获取临床结果详情数据。完整响应结构请参见本页的响应结构与成功响应示例。

在哪里可以找到 [B032] 药物临床结果基本信息的 OpenAPI schema？

OpenAPI schema 位于 /openapi.json#/paths/~1synapse~1ct-result~1detail/get，也可在 /openapi.json 浏览完整规范。

[B032] 药物临床结果基本信息

Q: [B032] 药物临床结果基本信息 是什么？

通过临床结果ID获取临床结果详情数据

Q: [B032] 药物临床结果基本信息 的接口地址是什么？

[B032] 药物临床结果基本信息 的接口为 GET https://connect.zhihuiya.com/synapse/ct-result/detail。

get

https://connect.zhihuiya.com/synapse/ct-result/detail

在体验中心中试用

通过临床结果ID获取临床结果详情数据

请求参数

此 API 接口支持的参数列表

名称	类型	示例	描述
`ct_result_id`	`string`	`e8ea588d3590e929a8022420da25d555`	临床结果ID，通过临床结果检索接口获取

响应结构

API 响应数据的结构说明

字段名	类型	示例	描述
`data`	`object`	-	响应数据
`drug`	`array`	`[ { "drug_id": "2838b95ade834c96b17ac8bcd2b68c27", "display_name": [ { "lang": "EN", "name": "Sotorasib" }, { "lang": "CN", "name": "索托拉西布" } ] } ]`	干预药详情
`drug_id`	`string`	`e82b83b42eba4e5ea3f26f8e06081a5a`	药物ID
`display_name`	`array`	`[ { "lang": "EN", "name": "Ranibizumab (Genentech)" }, { "lang": "CN", "name": "雷珠单抗" } ]`	药物名称，引用“CommonName”
`lang`	`string`	`EN`	语言
`name`	`string`	`Ranibizumab (Genentech)`	药物、靶点、机构、适应症、国家/地区、字典、作用机制名称
`phase`	`object`	`{ "display_name": [ { "lang": "EN", "name": "Not Applicable" }, { "lang": "CN", "name": "N/A" } ], "normalized_id": "ab5cf80923724fe3964bf485b1ba13fe" }`	分期详情
`display_name`	`array`	`[ { "lang": "EN", "name": "Autologous CAR-T" }, { "lang": "CN", "name": "自体CAR-T" } ]`	字典名称
`normalized_id`	`string`	`2fbfdb3e92d942c48cbb0adb79f23526`	字典ID
`title`	`string`	`Matching-Adjusted Indirect Treatment Comparisons (MAIC) of Sotorasib 960mg (soto960) Plus Panitumumab (pani) Vs. Trifluridine/Tipiracil(T/T) Plus Bevacizumab (bev) in Chemorefractory Metastatic Colorectal Cancer (mCRC)`	标题
`target`	`array`	`[ { "target_id": "8556307199154d34b1f9bc9685f2ec47", "short_name": [ { "lang": "EN", "name": "IL-6RA" } ], "display_name": [ { "lang": "EN", "name": "Interleukin-6 receptor alpha subunit" }, { "lang": "CN", "name": "白细胞介素-6受体α亚基" } ] } ]`	靶点
`target_id`	`string`	`1c2067e5ab054a8995f73efcfcf56207`	靶点ID
`short_name`	`array`	`[ { "lang": "EN", "name": "VEGF" } ]`	靶点简称，引用“CommonName”
`display_name`	`array`	`[ { "lang": "EN", "name": "Vascular endothelial growth factor" }, { "lang": "CN", "name": "血管内皮生长因子" } ]`	靶点全称，引用“CommonName”
`biomarker`	`array`	`[ { "id": "11acf267a4fc42f392751e023482aac3", "display_name": [ { "lang": "EN", "name": "CTNNB1 Mutation" } ] } ]`	生物标记物详情
`id`	`string`	`11acf267a4fc42f392751e023482aac3`	ID
`display_name`	`array`	`[ { "lang": "EN", "name": "CTNNB1 Mutation" } ]`	名称，引用“CommonName”
`conclusion`	`string`	`Sotorasib-panitumumab demonstrated acceptable safety with promising efficacy in chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer.`	结论
`related_id`	`array`	`[ { "id_type": "study_identifier", "id_value": "CodeBreaK 300" } ]`	试验代号
`id_type`	`string`	`study_identifier`	ID类型，study_identifier:试验代号
`id_value`	`string`	`DESTINY-Breast04`	value
`ct_result_id`	`string`	`5400a5a2dee3da90dd52408a3585d805`	临床结果ID
`organization`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Amgen, Inc." }, { "lang": "CN", "name": "安进股份有限公司" } ], "organization_id": "11ef8a9e8bf5ca80213a1183511cded3" } ]`	申办/合作机构
`display_name`	`array`	`[ { "lang": "EN", "name": "Roche Holding AG" }, { "lang": "CN", "name": "罗氏" } ]`	机构名称，引用“CommonName”
`organization_id`	`string`	`87bfaf037f8e60c9e25595cd98bb27e4`	机构ID
`study_design`	`object`	`{ "allocation_normalized": { "display_name": [ { "lang": "EN", "name": "Non-Randomized" }, { "lang": "CN", "name": "非随机化" } ], "normalized_id": "f2deb94314e73728bc13bedb47273b6b" }, "intervention_model_normalized": { "display_name": [ { "lang": "EN", "name": "Sequential Assignment" }, { "lang": "CN", "name": "序贯设计" } ], "normalized_id": "4c2fcb852d2837e883c15d260612e7c3" } }`	试验设计
`masking`	`string`	`XXXX`	Masking
`allocation`	`string`	`XXXX`	随机化
`primary_purpose`	`string`	`XXXX`	Primary Purpose
`intervention_model`	`string`	`XXXX`	设计类型
`allocation_normalized`	`object`	`Please check the form:ViewDto`	随机化详情
`intervention_model_normalized`	`object`	`Please check the form:ViewDto`	设计类型详情
`therapy_type`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Third line" }, { "lang": "CN", "name": "三线" } ], "normalized_id": "62662f0b1d5b3fafabeb571a211e9a31" } ]`	疗法类型详情
`published_time`	`integer<int64>`	`1719446400000`	发表时间
`register_number`	`array`	`[ "NCT05198934" ]`	登记号
`single_or_multi`	`string`	`single_drug`	单药/联合，single_drug:单药;multiple_drugs:联合
`mechanism_action`	`array`	`[ { "short_name": [ { "lang": "EN", "name": "IL-6RA antagonists" }, { "lang": "CN", "name": "IL-6RA拮抗剂" } ], "display_name": [ { "lang": "EN", "name": "Interleukin-6 receptor alpha subunit antagonists" }, { "lang": "CN", "name": "白细胞介素-6受体α亚基拮抗剂" } ], "mechanism_id": "b30a0bdb2e0bd9c03a908a84588c4217" } ]`	作用机制
`short_name`	`array`	`[ { "lang": "EN", "name": "KRAS G12C inhibitors" }, { "lang": "CN", "name": "KRAS G12C抑制剂" } ]`	作用机制简称
`display_name`	`array`	`[ { "lang": "EN", "name": "GTPase KRas G12C inhibitors" }, { "lang": "CN", "name": "KRAS G12C突变抑制剂" } ]`	作用机制名称
`mechanism_id`	`string`	`27c0848a265e4332836e10d0e8202b4c`	作用机制ID
`therapeutic_area`	`array`	`[ { "disease_id": "042cbe45c973477b957717ded29ef7b6", "display_name": [ { "lang": "EN", "name": "Nervous System Diseases" }, { "lang": "CN", "name": "神经系统疾病" } ] } ]`	治疗领域
`disease_id`	`string`	`06a9082fe1ec4c97bea31d888b9cfdce`	适应症ID
`display_name`	`array`	`[ { "lang": "EN", "name": "Uveitic Macular Edema" }, { "lang": "CN", "name": "葡萄膜炎黄斑水肿" } ]`	适应症名称，引用“CommonName”
`condition_disease`	`array`	`[ { "disease_id": "e35ce4e9b7a846d49e600ce7ac4a7fd6", "display_name": [ { "lang": "EN", "name": "Metastatic Colorectal Carcinoma" }, { "lang": "CN", "name": "转移性结直肠癌" } ] } ]`	适应症详情
`general_evaluation`	`object`	`{ "display_name": [ { "lang": "EN", "name": "Positive" }, { "lang": "CN", "name": "积极" } ], "normalized_id": "3289297424e03eda9b788c083bbf3147" }`	评价
`original_biomarker`	`array`	`[ { "name": "IL-6" } ]`	生物标记物原始值
`overall_enrollment`	`integer<int32>`	`100`	评价人数
`register_number_map`	`object`	`{ "NCT04737187": "5a4a2ad359d8a855d925943e23a58845" }`	登记号字典
`sponsor_organization`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Amgen, Inc." }, { "lang": "CN", "name": "安进股份有限公司" } ], "organization_id": "11ef8a9e8bf5ca80213a1183511cded3" } ]`	申办机构
`collaborator_organization`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Amgen, Inc." }, { "lang": "CN", "name": "安进股份有限公司" } ], "organization_id": "11ef8a9e8bf5ca80213a1183511cded3" } ]`	合作机构
`status` 必填	`boolean`	`false`	状态
`error_msg`	`string`	`The request parameter format is incorrect！`	错误信息
`error_code` 必填	`integer`	`0`	错误代码

成功响应示例

成功调用 API 的响应示例

JSON

{
  "data": {
    "drug": [
      {
        "drug_id": "e82b83b42eba4e5ea3f26f8e06081a5a",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "phase": {
      "display_name": [
        {
          "lang": "EN",
          "name": "Ranibizumab (Genentech)"
        }
      ],
      "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
    },
    "title": "Matching-Adjusted Indirect Treatment Comparisons (MAIC) of Sotorasib 960mg (soto960) Plus Panitumumab (pani) Vs. Trifluridine/Tipiracil(T/T) Plus Bevacizumab (bev) in Chemorefractory Metastatic Colorectal Cancer (mCRC)",
    "target": [
      {
        "target_id": "1c2067e5ab054a8995f73efcfcf56207",
        "short_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "biomarker": [
      {
        "id": "11acf267a4fc42f392751e023482aac3",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "conclusion": "Sotorasib-panitumumab demonstrated acceptable safety with promising efficacy in chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer.",
    "related_id": [
      {
        "id_type": "study_identifier",
        "id_value": "DESTINY-Breast04"
      }
    ],
    "ct_result_id": "5400a5a2dee3da90dd52408a3585d805",
    "organization": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
      }
    ],
    "study_design": {
      "masking": "XXXX",
      "allocation": "XXXX",
      "primary_purpose": "XXXX",
      "intervention_model": "XXXX",
      "allocation_normalized": {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
      },
      "intervention_model_normalized": {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
      }
    },
    "therapy_type": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
      }
    ],
    "published_time": 1719446400000,
    "register_number": [
      "NCT05198934"
    ],
    "single_or_multi": "single_drug",
    "mechanism_action": [
      {
        "short_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "mechanism_id": "27c0848a265e4332836e10d0e8202b4c"
      }
    ],
    "therapeutic_area": [
      {
        "disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "condition_disease": [
      {
        "disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "general_evaluation": {
      "display_name": [
        {
          "lang": "EN",
          "name": "Ranibizumab (Genentech)"
        }
      ],
      "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
    },
    "original_biomarker": [
      {
        "lang": "EN",
        "name": "Ranibizumab (Genentech)"
      }
    ],
    "overall_enrollment": 100,
    "register_number_map": {
      "NCT04737187": "5a4a2ad359d8a855d925943e23a58845"
    },
    "sponsor_organization": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
      }
    ],
    "collaborator_organization": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
      }
    ]
  },
  "status": true,
  "error_code": 0
}

错误码

此接口可能返回的错误码列表

业务错误码

错误码	描述
`68300004`	请求参数异常!
`68300005`	查询Api失败!
`68300006`	解析基本存取错误!
`68300007`	存在错误的请求!
`68300008`	服务中断异常，请稍后再试!
`68300010`	文件不符合上传规范!

平台错误码

错误码	描述
`67200001`	API整体限流错误!
`67200002`	用户调用请求限流限制错误!
`67200003`	申请token的key和secret不正确或者状态错误!
`67200004`	无权限或该接口的套餐已超过系统设置的上限!
`67200005`	账户余额不足，调用失败!
`67200006`	客户端已过期，调用失败!
`67200007`	超过调用额度，调用失败!

HTTP 状态码

状态码	描述
`0`	请求成功
`401`	Unauthorized
`403`	Forbidden
`404`	Not Found

性能指标

此接口的预期性能特征

正常响应时间

5000 ms

最大响应时间

10000 ms